Friday, January 27, 2017

BRIEF-Amgen receives positive CHMP opinion for ABP 501

* Amgen receives positive CHMP opinion for ABP 501

(biosimilar adalimumab) for the treatment of certain

inflammatory diseases

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)